drug · antibody drug conjugate
patient view →trastuzumab deruxtecan
Marketedupdated 2mo agoby Daiichi Sankyo Co Ltd🔗 ChEMBL
Approvedcommunity read0 votes
Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 12 investigational indications.
indications
investigational
NSCLCColorectal Cancer
targets
Receptor tyrosine-protein kinase erbB-2DNA topoisomerase 1
all catalysts(13)
approval · 13
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that